|
19 Companies |
|
16 Products |
|
16 Products |
|
27 Mechanisms of Action |
|
1 Trial |
|
40 News |
|
| 12» |
- | doxazosin mesylate / Generic mfg.
Trial completion: PRESCRIPT: Phenoxybenzamine Versus Doxazosin in PCC Patients (clinicaltrials.gov) - Jan 31, 2018
P4, N=134, Completed, Sponsor: University Medical Center Groningen
Recruiting --> Completed
- | vatalanib (PTK787) / Novartis, Bayer
Trial completion, Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1, N=96, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
- | doxazosin mesylate / Generic mfg.
Trial primary completion date: PRESCRIPT: Phenoxybenzamine Versus Doxazosin in PCC Patients (clinicaltrials.gov) - Oct 26, 2017
P4, N=134, Recruiting, Sponsor: University Medical Center Groningen
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009 Trial primary completion date: May 2017 --> Dec 2017
- | Azedra (iobenguane I 131) / Lantheus
Trial completion: 131MIBG to Treat Malignant Pheochromocytoma (clinicaltrials.gov) - Jun 30, 2017
P2, N=32, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: May 2017 --> Dec 2017 Suspended --> Completed
- ||||||| Trial completion: Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors (clinicaltrials.gov) - Apr 27, 2017
P2/3, N=200, Completed, Sponsor: Radio Isotope Therapy of America
Suspended --> Completed Active, not recruiting --> Completed
- | vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 22, 2017
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- NN1213 / Novo Nordisk
Trial completion, Enrollment change, Metastases: Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - Jun 21, 2016
P1, N=27, Completed, Sponsor: O'Dorisio, M S
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=35 --> 27
- | Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 13, 2016
P1, N=19, Completed, Sponsor: University of Southern California
Recruiting --> Completed | N=35 --> 27 Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Trial primary completion date, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - May 13, 2016
P1, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014
- vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 16, 2016
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- linsitinib (ASP7487) / Sling Therap
Trial completion, Enrollment change, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 11, 2016
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | N=40 --> 20
- Azedra (iobenguane I 131) / Lantheus, Caprelsa (vandetanib) / Sanofi
Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma (clinicaltrials.gov) - Dec 16, 2015
P1, N=0, Withdrawn, Sponsor: University College, London
Active, not recruiting --> Completed | N=40 --> 20 N=18 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2017 --> Dec 2015
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Dec 9, 2015
P1, N=27, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=18 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2017 --> Dec 2015 N=19 --> 27
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial termination, Trial primary completion date, Metastases: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma (clinicaltrials.gov) - May 26, 2015
P2, N=6, Terminated, Sponsor: National Cancer Institute (NCI)
N=19 --> 27 N=38 --> 6 | Suspended --> Terminated | Trial primary completion date: Feb 2015 --> Nov 2014; Slow Accrual
- | everolimus / Generic mfg.
Trial completion, Monotherapy: PheoCarcRAD001: RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid (clinicaltrials.gov) - May 20, 2015
P2, N=33, Completed, Sponsor: Seoul National University Hospital
N=38 --> 6 | Suspended --> Terminated | Trial primary completion date: Feb 2015 --> Nov 2014; Slow Accrual Recruiting --> Completed
- linsitinib (ASP7487) / Sling Therap
Trial primary completion date, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - May 1, 2015
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2015
- || vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 19, 2015
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2016 --> Dec 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- linsitinib (ASP7487) / Sling Therap
Enrollment change, Trial primary completion date, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Apr 17, 2015
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2015 N=20 --> 40 | Trial primary completion date: Dec 2013 --> Dec 2016
- doxazosin mesylate / Generic mfg.
Trial primary completion date: PRESCRIPT: Phenoxybenzamine Versus Doxazosin in PCC Patients (clinicaltrials.gov) - Feb 5, 2015
P4, N=134, Recruiting, Sponsor: University Medical Centre Groningen
N=20 --> 40 | Trial primary completion date: Dec 2013 --> Dec 2016 Trial primary completion date: May 2013 --> May 2017
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma (clinicaltrials.gov) - Dec 12, 2014
P2, N=38, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2013 --> May 2017 Trial primary completion date: Jan 2014 --> Feb 2015
- Azedra (iobenguane I 131) / Lantheus, Caprelsa (vandetanib) / Sanofi
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma (clinicaltrials.gov) - Dec 7, 2014
P1, N=18, Recruiting, Sponsor: University College, London
Trial primary completion date: Jan 2014 --> Feb 2015 Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Oct 2014 | Trial primary completion date: Apr 2016 --> Jan 2017
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial primary completion date, Metastases: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma (clinicaltrials.gov) - Dec 5, 2014
P2, N=6, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Oct 2014 | Trial primary completion date: Apr 2016 --> Jan 2017 N=38 --> 6 | Trial primary completion date: Feb 2015 --> Jan 2014
- | Granocyte (lenograstim) / Roche
Trial completion, Surgery: EORTC-STBSG 62931: Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P3, N=350, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=38 --> 6 | Trial primary completion date: Feb 2015 --> Jan 2014 Active, not recruiting --> Completed
- Trial termination: Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Jul 2, 2014
P1, N=35, Terminated, Sponsor: Yale University
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- || vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 19, 2014
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Terminated Trial primary completion date: Sep 2014 --> Dec 2014
- Trial completion: Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=60, Completed, Sponsor: University Hospital, Rouen
Trial primary completion date: Sep 2014 --> Dec 2014 Recruiting --> Completed
- linsitinib (ASP7487) / Sling Therap
Enrollment change, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - May 26, 2014
P2, N=20, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=40 --> 20
- | Enrollment closed: Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors (clinicaltrials.gov) - Apr 1, 2014
P2/3, N=200, Active, not recruiting, Sponsor: Radio Isotope Therapy of America
N=40 --> 20 Recruiting --> Active, not recruiting
- Votrient (pazopanib) / Novartis, BeiGene
Trial suspension, Metastases: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma (clinicaltrials.gov) - Mar 31, 2014
P2, N=38, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Suspended
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Mar 19, 2014
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=48 --> 19
- Trial completion: Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=10, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
N=48 --> 19 Recruiting --> Completed
- linsitinib (ASP7487) / Sling Therap
Enrollment closed, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 16, 2014
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma (clinicaltrials.gov) - Feb 11, 2014
P=N/A, N=15, Completed, Sponsor: Medical University of Vienna
Recruiting --> Active, not recruiting Recruiting --> Completed
- | New P4 trial: Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy (clinicaltrials.gov) - Oct 8, 2013
P4, N=65, Completed, Sponsor: Jagiellonian University
- Trial completion: Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy (clinicaltrials.gov) - Oct 7, 2013
P4, N=65, Completed, Sponsor: Jagiellonian University
Recruiting --> Completed Not yet recruiting --> Completed
- Azedra (iobenguane I 131) / Lantheus, Caprelsa (vandetanib) / Sanofi
New P1 trial, Metastases: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma (clinicaltrials.gov) - Sep 9, 2013
P1, N=18, Not yet recruiting, Sponsor: University College, London
- Trial termination, HEOR: Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma (clinicaltrials.gov) - Jun 6, 2013
P=N/A, N=24, Terminated, Sponsor: Molecular Insight Pharmaceuticals, Inc.
Not yet recruiting --> Completed Recruiting --> Terminated
- Avastin (bevacizumab) / Roche
Enrollment change: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease (clinicaltrials.gov) - Nov 4, 2012
P=N/A, N=22, Completed, Sponsor: University Medical Centre Groningen
Recruiting --> Terminated N=30 --> 22
- Avastin (bevacizumab) / Roche
Trial completion: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease (clinicaltrials.gov) - Nov 4, 2012
P=N/A, N=22, Completed, Sponsor: University Medical Centre Groningen
N=30 --> 22 Recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Oct 23, 2012
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial completion: Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors (clinicaltrials.gov) - Oct 23, 2012
P1, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: SWOG-EORTC-62933: Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 9, 2012
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial termination: Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors (clinicaltrials.gov) - May 16, 2012
P2, N=10, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Terminated; due to slow accrual
- linsitinib (ASP7487) / Sling Therap
New P2 trial, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Mar 20, 2012
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Tavalisse (fostamatinib) / Rigel
Enrollment change, Metastases: A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... (clinicaltrials.gov) - Feb 6, 2012
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; due to slow accrual N=285 --> 37
- Tavalisse (fostamatinib) / Rigel
Trial completion, Metastases: A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... (clinicaltrials.gov) - Feb 6, 2012
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
N=285 --> 37 Recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 31, 2012
P1, N=19, Active, not recruiting, Sponsor: University of Southern California
Recruiting --> Completed Recruiting --> Active, not recruiting
- doxazosin mesylate / Generic mfg.
Trial initiation date: PRESCRIPT: Phenoxybenzamine Versus Doxazosin in PCC Patients (clinicaltrials.gov) - Jan 24, 2012
P4, N=134, Recruiting, Sponsor: University Medical Centre Groningen
Recruiting --> Active, not recruiting Initiation date: Jul 2011 --> Dec 2011
- doxazosin mesylate / Generic mfg.
Enrollment open: PRESCRIPT: Phenoxybenzamine Versus Doxazosin in PCC Patients (clinicaltrials.gov) - Jan 24, 2012
P4, N=134, Recruiting, Sponsor: University Medical Centre Groningen
Initiation date: Jul 2011 --> Dec 2011 Not yet recruiting --> Recruiting
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Metastases: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma (clinicaltrials.gov) - Oct 24, 2011
P2, N=38, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=78 --> 38